Revive Therapeutics Ltd. (TSXV:RVV), a cannabinoid biopharma stock, jumped after receiving an orphan drug designation for the treatment of autoimmune hepatitis
A U.S. Food and Drug Administration designation was good news for investors in a cannabinoid biopharma stock Wednesday. Here’s some small stocks making big moves on Wednesday, June 27, 2018 (as of 4 pm EST):
Revive Therapeutics Ltd. (TSXV:RVV), a cannabinoid biopharma stock, powered 17% higher to $0.24 on Wednesday after announcing that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for cannabidiol in the treatment of autoimmune hepatitis.
As well, shares of Titan Medical Inc. (TSX:TMD) added 9% at $7.78 as the medical device company said its common stock will begin trading on the Nasdaq Capital Market on June 27, 2018 under the symbol ‘TMDI’.
iCo Therapeutics Inc. (TSXV:ICO), meanwhile, reported a positive primary end point of safety and tolerability in its Phase 1 clinical study of iCo-019 (Oral Amp B). iCo Therapeutics stock popped 33% to $0.18 following the announcement.
Finally, Diamond Estates Wines & Spirits Inc. (TSX:DWS) shares fell 17% to $0.315 as the alcoholic beverages producer/marketer announced that its fourth-quarter 2018 revenue slipped 11% to $5.4 million.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Revive Therapeutics Ltd. (TSXV:RVV), a cannabinoid biopharma stock, powered 17% higher to $0.24 on Wednesday after announcing that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for cannabidiol in the treatment of autoimmune hepatitis.
